The estimated Net Worth of Elaine O'hara is at least $241 ezer dollars as of 1 March 2024. Elaine hara owns over 19,600 units of Novavax stock worth over $240,884 and over the last 2 years Elaine sold NVAX stock worth over $0.
Elaine has made over 1 trades of the Novavax stock since 2024, according to the Form 4 filled with the SEC. Most recently Elaine exercised 19,600 units of NVAX stock worth $105,644 on 1 March 2024.
The largest trade Elaine's ever made was exercising 19,600 units of Novavax stock on 1 March 2024 worth over $105,644. On average, Elaine trades about 6,533 units every 0 days since 2023. As of 1 March 2024 Elaine still owns at least 19,600 units of Novavax stock.
You can see the complete history of Elaine hara stock trades at the bottom of the page.
Elaine's mailing address filed with the SEC is C/O NOVAVAX, INC., 700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi és Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: